Immunotherapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
Open Access
- 20 August 2024
- journal article
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 12 (2) , 72-81
Abstract
Sung Eun Kim, Kyoungwon Jung, Moo In Park. Journal of Digestive Cancer Research 2024;12:72-81. https://doi.org/10.52927/jdcr.2024.12.2.72Keywords
This publication has 37 references indexed in Scilit:
- Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trialCancer Medicine, 2024
- Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinomaCancer, 2022
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialCancer Cell, 2022
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA, 2021
- LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 studyAnnals of Oncology, 2021
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2021
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusJAMA Oncology, 2019
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic ApproachesCardioVascular and Interventional Radiology, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017